What is Anixa Biosciences Inc's earnings per share (EPS)?

Anixa Biosciences Inc (ANIX) reported diluted earnings per share of $-0.34 for fiscal year 2025. This represents a 12.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Anixa Biosciences Inc Financials

ANIX

Source SEC Filings (10-K/10-Q) Updated Mar 9, 2026 Currency USD FYE October

This page shows Anixa Biosciences Inc (ANIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Anixa Biosciences Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.66x

For every $1 of reported earnings, Anixa Biosciences Inc generates $0.66 in operating cash flow (-$7.2M OCF vs -$10.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$10.9M

YoY+13.0%

Anixa Biosciences Inc reported -$10.9M in net income in fiscal year 2025. This represents an increase of 13.0% from the prior year.

EPS (Diluted)

$-0.34

YoY+12.8%

Anixa Biosciences Inc earned $-0.34 per diluted share (EPS) in fiscal year 2025. This represents an increase of 12.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.5M

YoY+46.9%

5Y CAGR-33.6%

10Y CAGR-9.0%

Anixa Biosciences Inc held $1.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

33M

YoY+3.7%

5Y CAGR+5.1%

10Y CAGR+14.4%

Anixa Biosciences Inc had 33M shares outstanding in fiscal year 2025. This represents an increase of 3.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-72.5%

YoY-2.1pp

5Y CAGR+1.2pp

10Y CAGR-34.1pp

Anixa Biosciences Inc's ROE was -72.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$5.1M

YoY-20.7%

5Y CAGR+3.0%

10Y CAGR+21.7%

Anixa Biosciences Inc invested $5.1M in research and development in fiscal year 2025. This represents a decrease of 20.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ANIX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	$210K0.0%	$210K	N/A	$512K	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.1M-20.7%	$6.4M+34.1%	$4.8M-28.9%	$6.7M+8.3%	$6.2M+41.3%	$4.4M
SG&A Expenses	$6.6M-10.8%	$7.4M+18.2%	$6.3M-12.3%	$7.2M+1.4%	$7.1M+26.4%	$5.6M
Operating Income	-$11.7M+15.4%	-$13.8M-25.6%	-$11.0M+20.6%	-$13.9M-5.6%	-$13.1M-31.6%	-$10.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$10.9M+13.0%	-$12.6M-28.0%	-$9.8M+27.8%	-$13.6M-4.9%	-$13.0M-29.3%	-$10.0M
EPS (Diluted)	$-0.34+12.8%	$-0.39-21.9%	$-0.32-171.1%	$0.45	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.1M0.0%	$1.1M	N/A	$1.1M-20.2%	$1.3M-14.8%	$1.6M	N/A	$1.9M
SG&A Expenses	$1.6M0.0%	$1.6M	N/A	$1.4M-17.8%	$1.7M-8.3%	$1.8M	N/A	$1.7M
Operating Income	-$2.7M0.0%	-$2.7M	N/A	-$2.4M+18.9%	-$3.0M+11.3%	-$3.4M	N/A	-$3.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.6M0.0%	-$2.6M	N/A	-$2.3M+19.1%	-$2.8M+12.4%	-$3.2M	N/A	-$3.3M
EPS (Diluted)	$-0.080.0%	$-0.08	N/A	$-0.07+22.2%	$-0.09+10.0%	$-0.10	N/A	$-0.10

ANIX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$15.2M-19.4%	$18.9M-25.5%	$25.4M-10.4%	$28.3M-19.7%	$35.2M+141.3%	$14.6M
Current Assets	$15.1M-19.5%	$18.7M-25.9%	$25.2M-10.3%	$28.1M-19.7%	$35.0M+140.3%	$14.6M
Cash & Equivalents	$1.5M+46.9%	$1.1M+5.5%	$998K-89.8%	$9.8M-67.1%	$29.8M+148.5%	$12.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.4M-36.8%	$2.2M+24.0%	$1.8M+26.8%	$1.4M-30.2%	$2.0M+98.7%	$1.0M
Current Liabilities	$1.2M-38.2%	$2.0M+20.4%	$1.7M+34.7%	$1.2M-31.1%	$1.8M+17.1%	$1.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$15.1M-15.5%	$17.9M-27.4%	$24.6M-11.5%	$27.8M-18.2%	$34.0M+149.7%	$13.6M
Retained Earnings	-$254.2M-4.2%	-$243.9M-5.4%	-$231.5M-4.9%	-$220.7M-5.8%	-$208.6M-7.5%	-$194.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	N/A	$15.2M-5.3%	$16.1M-8.9%	$17.7M+4.0%	$17.0M-10.2%	$18.9M-12.4%	$21.6M-5.7%	$22.9M
Current Assets	N/A	$15.1M-5.3%	$15.9M-9.0%	$17.4M+4.1%	$16.8M-10.3%	$18.7M-12.5%	$21.4M-5.8%	$22.7M
Cash & Equivalents	N/A	$1.5M+24.4%	$1.2M-16.8%	$1.5M-21.7%	$1.9M+81.4%	$1.1M-17.2%	$1.3M+3.8%	$1.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$1.4M-34.9%	$2.1M-4.9%	$2.2M+8.2%	$2.1M-5.6%	$2.2M-18.9%	$2.7M+21.9%	$2.2M
Current Liabilities	N/A	$1.2M-37.2%	$2.0M-4.8%	$2.1M+9.5%	$1.9M-5.6%	$2.0M-20.0%	$2.5M+24.8%	$2.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$15.1M-0.6%	$15.2M-8.6%	$16.6M+3.3%	$16.1M-10.0%	$17.9M-10.7%	$20.0M-8.1%	$21.8M
Retained Earnings	N/A	-$254.2M-1.0%	-$251.7M-1.1%	-$249.0M-0.9%	-$246.7M-1.1%	-$243.9M-1.3%	-$240.8M-1.2%	-$237.9M

ANIX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$7.2M+2.2%	-$7.3M-18.1%	-$6.2M+4.4%	-$6.5M-31.5%	-$4.9M+20.0%	-$6.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$16K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$6.2M
Investing Cash Flow	$4.9M+13.8%	$4.3M+176.3%	-$5.6M+47.8%	-$10.7M-173.9%	-$3.9M-1180.9%	-$306K
Financing Cash Flow	$2.3M-33.2%	$3.4M+833.1%	$366K-19.0%	$452K-98.6%	$31.6M+235.6%	$9.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$6K	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.6M0.0%	-$2.6M-108.0%	-$1.3M+16.9%	-$1.5M-0.5%	-$1.5M+48.2%	-$2.9M-213.3%	-$927K+64.9%	-$2.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$1.2M0.0%	$1.2M+87.8%	$654K+178.5%	-$833K-135.6%	$2.3M-13.4%	$2.7M+211.8%	$867K-68.2%	$2.7M
Financing Cash Flow	$1.7M0.0%	$1.7M+381.4%	$350K-81.9%	$1.9M+10616.7%	$18K+205.9%	-$17K-116.0%	$106K-28.9%	$149K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ANIX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-6586.2%-1342.9pp	-5243.3%	N/A	-2565.6%	N/A
Net Margin	N/A	-5978.1%-1306.2pp	-4671.9%	N/A	-2530.1%	N/A
Return on Equity	-72.5%-2.1pp	-70.3%-30.5pp	-39.9%+9.1pp	-48.9%-10.8pp	-38.1%+35.5pp	-73.7%
Return on Assets	-71.7%-5.3pp	-66.4%-27.7pp	-38.7%+9.4pp	-48.0%-11.3pp	-36.8%+31.8pp	-68.6%
Current Ratio	12.18+2.8	9.35-5.8	15.19-7.6	22.81+3.2	19.58+10.0	9.55
Debt-to-Equity	0.09-0.0	0.12+0.1	0.07+0.0	0.050.0	0.06-0.0	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-17.0%	N/A	-13.6%+3.8pp	-17.4%+0.5pp	-17.8%	N/A	-15.0%
Return on Assets	N/A	-16.8%	N/A	-12.8%+3.6pp	-16.4%+0.4pp	-16.8%	N/A	-14.3%
Current Ratio	N/A	12.18+4.1	8.08-0.4	8.45-0.4	8.88-0.5	9.35+0.8	8.54-2.8	11.31
Debt-to-Equity	N/A	0.09-0.0	0.140.0	0.140.0	0.130.0	0.12-0.0	0.14+0.0	0.10
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Tscan Therapeutics, Inc. TCRX

$57.5M

Surrozen Inc SRZN

$320.1M

Shattuck Labs, Inc. STTK

$459.4M

Pyxis Oncology, Inc. PYXS

$93.0M

Adagene Inc. ADAG

$188.1M

Frequently Asked Questions

Is Anixa Biosciences Inc profitable?

No, Anixa Biosciences Inc (ANIX) reported a net income of -$10.9M in fiscal year 2025.

What is Anixa Biosciences Inc's return on equity (ROE)?

Anixa Biosciences Inc (ANIX) has a return on equity of -72.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Anixa Biosciences Inc's operating cash flow?

Anixa Biosciences Inc (ANIX) generated -$7.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Anixa Biosciences Inc's total assets?

Anixa Biosciences Inc (ANIX) had $15.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Anixa Biosciences Inc spend on research and development?

Anixa Biosciences Inc (ANIX) invested $5.1M in research and development during fiscal year 2025.

How many shares does Anixa Biosciences Inc have outstanding?

Anixa Biosciences Inc (ANIX) had 33M shares outstanding as of fiscal year 2025.

What is Anixa Biosciences Inc's current ratio?

Anixa Biosciences Inc (ANIX) had a current ratio of 12.18 as of fiscal year 2025, which is generally considered healthy.

What is Anixa Biosciences Inc's debt-to-equity ratio?

Anixa Biosciences Inc (ANIX) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Anixa Biosciences Inc's return on assets (ROA)?

Anixa Biosciences Inc (ANIX) had a return on assets of -71.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Anixa Biosciences Inc's cash runway?

Based on fiscal year 2025 data, Anixa Biosciences Inc (ANIX) had $1.5M in cash against an annual operating cash burn of $7.2M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Anixa Biosciences Inc's Piotroski F-Score?

Anixa Biosciences Inc (ANIX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Anixa Biosciences Inc's earnings high quality?

Anixa Biosciences Inc (ANIX) has an earnings quality ratio of 0.66x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.